Measure Tumor Growth Rate - Immunohistochemistry: KI-67

This predictive consultation package focuses on assessing the proliferative activity of tumor cells. It is based on measuring the KI-67 index, a nuclear protein expressed in all active cell cycle phases (G1, S, G2, M) except for the resting phase (G0). The package also includes complementary proliferative or predictive markers such as p53 (for tumor suppressor gene mutations) and subtype-specific markers (e.g., ER, PR, HER2 for breast cancer). The proportion of KI-67-positive cells (KI-67 index) is measured in the most active areas of the tumor, and this proportion is interpreted in the context of tumor type and other marker results to estimate biological grade, recurrence probability, and response to treatment.